查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1923001

按產品類型、技術、檢體類型、應用和最終用戶分類的即時檢測或快速診斷市場—2026-2032年全球預測

Point-Of-Care Or Rapid Diagnostics Market by Product Type, Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，即時檢測或快速診斷市場價值為 356.1 億美元，預計到 2026 年將成長至 386.2 億美元，年複合成長率為 9.56%，到 ​​2032 年將達到 675.2 億美元。

關鍵市場統計數據
基準年 2025 356.1億美元
預計年份：2026年 386.2億美元
預測年份 2032 675.2億美元
複合年成長率 (%) 9.56%

快速診斷在現代醫療保健服務中不斷演變的角色，以及它如何影響臨床和商業相關人員的策略重點。

在不斷變化的患者期​​望、技術小型化以及及時做出臨床決策的需求推動下，照護現場快速診斷已從邊緣臨床工具轉變為現代診療路徑的核心要素。本文回顧了當前情勢，重點闡述了診斷速度、可及性和準確性如何重塑門診、住院和家庭監測的工作流程。文章還概述了醫療設備製造商、診斷實驗室、支付方和醫療系統在臨床性能、易用性和成本控制方面所面臨的策略挑戰。

小型化檢測平台、整合式醫療服務模式和實證商業化的整合正在重塑即時診斷。

照護現場診斷領域正經歷技術、醫療服務模式和相關人員期望等方面的變革。分子方法、微流體整合和電化學感測技術的進步，使得以往需要在中心檢查室進行的檢測能夠在床邊或家中完成，且性能與中心實驗室相當。這些技術進步催生了新的醫療服務模式，包括行動檢測單元、擴展的家庭監測和整合式數位健康平台，從而重塑了診斷資訊融入臨床決策的路徑。因此，臨床團隊正在重新設計工作流程，將快速檢測結果納入同一診療方案，從而加快治療啟動速度並改善患者體驗。

美國近期關稅政策如何促使相關人員重組供應鏈、調整籌資策略、定價和合規措施。

美國2025年實施的新關稅制度和貿易政策引發了一系列貿易摩擦，對整個供應鏈的運作和策略都產生了即時影響。製造商和經銷商正在透過重新評估籌資策略、增加關鍵零件庫存以及實現供應商多元化來應對這些挑戰，以降低關稅波動帶來的風險。因此，採購團隊優先考慮對供應商進行實質審查，並在條件允許的情況下尋找近岸外包的機會；產品開發團隊則在評估如何透過設計變更來減少對高關稅零件的依賴，同時又不影響產品效能。

策略性細分互動涵蓋產品類型、最終用戶、應用、技術、分銷管道和檢體類型，指導產品和商業化優先排序。

深入了解市場區隔對於協調產品設計、證據產生和市場推廣策略至關重要。從產品類型來看，市場涵蓋凝血、內分泌、血液學、免疫化學、側向層析免疫檢測、分子診斷和尿液分析。凝血平台進一步細分為PT/INR檢測儀和血栓彈力圖儀；內分泌解決方案細分為血糖儀和胰島素幫浦；血液學細分為血紅蛋白儀和白血球計數儀；免疫化學細分為化學冷光免疫免疫檢測、酵素免疫分析法和螢光免疫分析；側向層析檢測細分為抗體、抗原和尿液檢查用於分子分析儀等溫次世代定序等溫序增序分析。了解這些產品之間的差異有助於明確每種環境下的效能、監管和易用性預期。

區域監管差異、採購趨勢和數位基礎設施正在推動美洲、歐洲、中東和非洲以及亞太地區採取差異化的策略。

區域趨勢差異顯著，應體現在打入市場策略和監管計畫的製定。在美洲，持續重視整合式醫療網路、基於價值的報銷試驗計畫以及醫療服務提供者的整合，正在塑造對能夠帶來可衡量療效和營運效率的醫療設備的需求。同時，歐洲、中東和非洲（EMEA）的監管和報銷環境各不相同，各國的衛生技術評估流程和採購慣例要求制定量身定做的打入市場策略。在一些國家，公開競標和與醫院集團的談判是產品推廣的關鍵。在亞太地區，市場成熟度因區域而異，一些市場正在迅速採用照護現場分子檢測和家庭監測解決方案，而另一些市場則優先考慮擴充性、低成本的側向層析和電化學平台，以擴大檢測範圍。

競爭格局結合了現有企業的規模、Start-Ups的敏捷性和策略聯盟，透過證據、連結性和使用者體驗來推動照護現場診斷領域的差異化。

照護現場領域的競爭格局由成熟的診斷設備製造商、快速發展的臨床Start-Ups和專業平台提供者組成。現有企業利用其豐富的產品系列、成熟的分銷網路和與醫院的現有關係來鞏固市場地位，而靈活的新參與企業則專注於以用戶為中心的設計、快速迭代以及針對特定應用場景和終端用戶群的循證項目。隨著連結性和數據分析能力成為貫穿整個醫療流程、釋放價值的差異化因素，診斷開發人員和數位醫療供應商之間的合作正在加速發展。

透過基於實證的產品和通路策略，採取切實有效的領導行動，確保臨床應用、供應保障和商業性擴充性。

產業領導者應採取積極進取、多管齊下的策略，整合產品開發、證據收集和商業性執行。優先考慮以最終用戶為中心的解決方案設計，在診所、醫院、醫生辦公室、行動檢測單元和居家照護環境中進行迭代式可用性研究，以減輕培訓負擔並最佳化工作流程整合。同時，投資於以循環系統、糖尿病監測、感染疾病學和妊娠檢測等應用領域為重點的實用性臨床試驗和真實世界證據項目，以在對支付方和醫療服務提供方至關重要的場景中證明臨床效用和經濟價值。

結合關鍵相關人員訪談、技術基準測試、文獻綜述以及產業趨勢和政策分析等多源研究途徑，確保得出切實可行的見解。

本分析的調查方法結合了多方面視角，旨在提供平衡且實用的觀點。主要研究包括對臨床醫生、採購負責人和行業高管進行結構化訪談，以了解醫院、診所、行動檢測服務機構、醫生辦公室和居家照護課程中的本地可用性見解和採購重點。次要研究則透過評估同儕審查文獻、監管指導文件和公共臨床試驗註冊庫，檢驗了技術趨勢和臨床證據的發展軌跡。

為尋求將快速診斷納入護理路徑和商業生態系統的產品開發人員和醫療保健領導者總結策略要務

總之，照護現場和快速診斷正處於策略轉折點，技術能力、醫療服務轉型和商業性創新在此交匯融合，重新定義了診斷決策的製定地點和方式。在這種環境下取得成功，需要的不僅僅是卓越的分析能力；它還需要整合策略，該戰略需兼顧臨床效用、用戶體驗、供應鏈韌性以及能夠引起支付方和醫療服務提供方共鳴的證據。那些能夠將產品開發與實際應用案例結合、積極管理地緣政治和關稅相關風險並部署靈活的分銷和商業化模式的利益相關人員，將更有利於抓住新的機會。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的即時診斷或快速診斷市場

  • 凝血
    • PT INR測量儀器
    • 血栓彈力圖裝置
  • 內分泌學
    • 血糖儀
    • 胰島素幫浦
  • 血液學
    • 血紅素測量裝置
    • 白血球計數器
  • 免疫化學
    • 化學冷光免疫檢測
    • 酵素免疫分析法
    • 螢光免疫分析
  • 側向流動免疫檢測
    • 抗體檢測
    • 抗原檢測
    • 多重測試
  • 分子診斷
    • 等溫擴增
    • 次世代定序
    • PCR
  • 尿液檢查
    • 分析儀器系統
    • 測試條

9. 按技術分類的即時診斷或快速診斷市場

  • 電化學檢測
  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
    • 螢光免疫分析
    • 側向流動免疫檢測
  • 微流體平台
  • 分子診斷
    • 等溫擴增
    • 次世代定序
    • PCR
  • 光學檢測

10. 按檢體類型分類的即時檢測或快速診斷市場

  • 血
  • 吐氣
  • 唾液
  • 尿

11. 按應用分類的即時診斷或快速診斷市場

  • 心臟病學
  • 糖尿病監測
  • 感染疾病
  • 腫瘤學
  • 妊娠測試

12. 按最終用戶分類的即時診斷或快速診斷市場

  • 診所
  • 居家照護
  • 醫院
  • 移動偵測
  • 醫生診所

13. 按地區分類的即時診斷或快速診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 按群體分類的即時診斷或快速診斷市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國即時診斷或快速診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國即時檢測或快速診斷市場

17. 中國即時診斷或快速診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acon Laboratories, Inc.
  • Becton Dickinson and Company
  • Chembio Diagnostic Systems, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings plc
  • Hologic, Inc.
  • Jianchun Biological Technology Co., Ltd.
  • Meridian Bioscience, Inc.
  • Nova Biomedical Corporation
  • OraSure Technologies, Inc.
  • Polymer Technology Systems, Inc.
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Response Biomedical Corp.
  • Samsung Electronics Co., Ltd.
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Trinity Biotech plc
  • Veredus Laboratories Pte Ltd
Product Code: MRR-867BED9A9EB7

The Point-Of-Care Or Rapid Diagnostics Market was valued at USD 35.61 billion in 2025 and is projected to grow to USD 38.62 billion in 2026, with a CAGR of 9.56%, reaching USD 67.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 35.61 billion
Estimated Year [2026] USD 38.62 billion
Forecast Year [2032] USD 67.52 billion
CAGR (%) 9.56%

Framing the evolving role of rapid diagnostics in contemporary healthcare delivery and strategic priorities for clinical and commercial stakeholders

Point-of-care and rapid diagnostics have moved from peripheral clinical tools to central elements of modern care pathways, driven by evolving patient expectations, technological miniaturization, and the imperative for timely clinical decision-making. This introduction frames the current landscape by highlighting how diagnostic speed, accessibility, and accuracy are reshaping workflows across ambulatory care, inpatient settings, and home-based monitoring. It outlines the strategic implications for device manufacturers, diagnostic laboratories, payers, and health systems who must reconcile clinical performance with usability and cost constraints.

The interplay between regulatory clarity and accelerated approval pathways has created an environment where innovation can translate to practice rapidly, provided that validation and real-world evidence are prioritized. In addition, shifting reimbursement models that emphasize value over volume are incentivizing solutions that demonstrably reduce downstream costs through early detection and treatment optimization. Taken together, these forces underscore an urgent need for clear product differentiation and robust evidence generation strategies as developers transition prototypes into scalable offerings. This introduction sets expectations for the subsequent sections by emphasizing practical adoption barriers, competitive levers, and strategic priorities that stakeholders must address to succeed in a dynamic point-of-care market.

Convergence of compact assay platforms, integrated care delivery models, and evidence-driven commercialization reshaping point-of-care diagnostics

The landscape for point-of-care diagnostics is undergoing transformative shifts that span technology, care delivery models, and stakeholder expectations. Advances in molecular methods, microfluidic integration, and electrochemical sensing are enabling assays that once required centralized laboratories to be performed at bedside or in-home with comparable performance characteristics. These technological advances are being accompanied by new care delivery models that incorporate mobile testing units, expanded home monitoring, and integrated digital health platforms, each reshaping the pathways by which diagnostic information flows into clinical decision-making. Consequently, clinical teams are reconfiguring workflows to incorporate rapid test results into same-encounter care plans, accelerating treatment initiation and improving patient experience.

Parallel to technical progress, commercial dynamics are evolving as distribution channels diversify and digital procurement gains traction. Evolving payer expectations and the need for demonstrable clinical utility are driving manufacturers to invest in outcomes studies and health economics evidence that can justify placement across hospitals, clinics, and home care. Furthermore, interoperability and data integration are becoming table stakes, as stakeholders demand secure and standardized methods to aggregate real-world diagnostic data for population health management and quality measurement. These combined shifts are recalibrating competitive advantage from purely analytical performance to include user experience, connectivity, and proven clinical impact.

How recent United States tariff developments have prompted supply chain realignment, procurement strategy adjustments, and pricing and compliance adaptations across stakeholders

The introduction of new tariff regimes and trade policies in the United States in 2025 introduced a set of trade-related frictions with immediate operational and strategic effects across supply chains. Manufacturers and distributors have responded by reassessing sourcing strategies, increasing inventories of critical components, and diversifying supplier bases to mitigate exposure to tariff volatility. As a result, procurement teams have prioritized supplier due diligence and nearshoring opportunities where feasible, while product development groups are evaluating design changes that reduce dependency on high-tariff components without compromising performance.

These policy-driven adjustments have also affected pricing strategies and contract negotiations across distribution channels, prompting suppliers to explore longer-term agreements with health systems and group purchasing organizations to stabilize demand and cash flow. In parallel, regulatory and customs compliance functions have assumed greater prominence within commercial operations, with firms investing in trade advisory capabilities and automated classification processes to optimize tariff outcomes. The cumulative effect of these adaptations has been a reframing of risk management practices across manufacturing, distribution, and commercial functions, reinforcing the importance of agile supply chain architectures and close coordination between procurement, regulatory, and commercial teams.

Strategic segmentation interplay across product types, end users, applications, technologies, distribution channels, and sample types to guide product and commercial prioritization

A granular understanding of segmentation is essential to align product design, evidence generation, and go-to-market approaches. When considering product type, the market spans coagulation, endocrinology, hematology, immunochemistry, lateral flow immunoassays, molecular diagnostics, and urinalysis, with coagulation platforms further split into PT INR meters and thromboelastography devices, endocrinology solutions including glucose meters and insulin pumps, hematology covering hemoglobin meters and white blood cell counters, immunochemistry comprising chemiluminescence immunoassay, enzyme linked immunosorbent assay, and fluorescence immunoassay, lateral flow tests including antibody tests, antigen tests, and multiplex tests, molecular diagnostics encompassing isothermal amplification, next generation sequencing, and PCR, and urinalysis delivered through analyzer systems and test strips. Understanding these product distinctions clarifies the performance, regulatory, and usability expectations across settings.

End user segmentation-spanning clinics, home care, hospitals, mobile testing, and physician offices-directly influences requirements for workflow integration, connectivity, and training. Applications such as cardiology, diabetes monitoring, infectious diseases, oncology, and pregnancy testing each impose unique analytical demands and evidence needs that shape clinical acceptance. Technology choices including electrochemical detection, immunoassay, microfluidic platforms, molecular diagnostics, and optical detection influence cost structures and scalability, with immunoassay technologies frequently represented by chemiluminescence, ELISA, fluorescence methods, and lateral flow formats, and molecular diagnostics often leveraging isothermal amplification, next generation sequencing, and PCR. Distribution channels, whether direct tender, distributor sales, e-commerce, or retail pharmacies, determine sales cycles and margin profiles. Finally, sample type considerations-blood, breath, saliva, and urine-affect collection workflows and user comfort, which in turn influence adoption in decentralized settings. Integrating these segmentation dimensions enables clearer prioritization of clinical validation, user experience design, and channel strategies.

Regional regulatory variability, procurement dynamics, and digital infrastructure differences driving differentiated strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics vary significantly and must inform go-to-market and regulatory planning. The Americas continue to emphasize integrated care networks, value-based reimbursement pilot programs, and consolidation among healthcare providers, which shapes demand for devices that deliver measurable outcomes and operational efficiencies. Meanwhile, Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where national-level health technology assessment processes and procurement practices require tailored market access strategies; in several countries, public tenders and hospital group negotiations remain pivotal for adoption. In the Asia-Pacific region, diverse market maturities coexist, with some markets rapidly adopting point-of-care molecular testing and home monitoring solutions, and others prioritizing scalable, low-cost lateral flow and electrochemical platforms to expand testing access.

These regional distinctions extend to supply chain considerations, where logistics, customs treatment, and regional manufacturing capacity influence where companies choose to localize production or hold safety stocks. Additionally, digital health infrastructure and interoperability standards differ across regions, affecting the ease with which connected diagnostic solutions can be integrated into electronic health records and national health information exchanges. A regionally nuanced approach that aligns evidence generation, pricing, and distribution with local regulatory and reimbursement realities will be essential for sustained adoption and commercial success.

Competitive dynamics combining incumbent scale, startup agility, and strategic partnerships to differentiate on evidence, connectivity, and user experience in point-of-care diagnostics

Competitive dynamics in point-of-care diagnostics are shaped by a mix of established diagnostic manufacturers, fast-moving clinical startups, and specialized platform providers. Incumbent firms leverage broad product portfolios, established distribution networks, and existing hospital relationships to defend market positions, while nimble entrants focus on user-centric design, rapid iteration, and targeted evidence programs to penetrate specific applications or end-user segments. Partnerships between diagnostic developers and digital health vendors are accelerating, as connectivity and data analytics capabilities become differentiating features that unlock value across care pathways.

In addition, strategic collaborations with contract manufacturers and component suppliers are increasingly common as firms seek to optimize production flexibility and reduce time-to-market for upgrades and new assays. Mergers and acquisitions remain an important route for expanding assay menus and enhancing technological capabilities, while licensing agreements enable quicker access to complementary technologies. Competitive advantage is therefore multifaceted: analytical performance remains necessary but not sufficient; companies that combine strong clinical validation, streamlined user experience, integrated data workflows, and flexible commercial models are best positioned to win adoption across clinical and non-traditional care settings.

Practical and high-impact actions for leaders to secure clinical adoption, supply resilience, and commercial scalability through evidence-driven product and channel strategies

Industry leaders should adopt a proactive, multi-dimensional strategy that aligns product development, evidence generation, and commercial execution. Prioritize designing solutions with end users in mind by conducting iterative usability studies in clinics, hospitals, physician offices, mobile testing units, and home care environments to reduce training burden and optimize workflow integration. Concurrently, invest in pragmatic clinical trials and real-world evidence programs focused on application areas such as cardiology, diabetes monitoring, infectious diseases, oncology, and pregnancy testing to demonstrate clinical utility and economic value in contexts that matter to payers and providers.

From an operational perspective, diversify supply chains and consider regional manufacturing or strategic inventory placement to reduce exposure to trade policy shocks. Embrace modular and platform-based product architectures that allow rapid assay updates and multi-analyte expansion without full system redesign. Commercially, tailor distribution strategies to the target end user and channel dynamics-direct tender and distributor sales for institutional clients, e-commerce and retail pharmacy strategies for consumer-facing products, and hybrid models where warranted. Finally, embed interoperability and secure data sharing into product roadmaps to support integration with electronic health records and population health tools, thereby enhancing stickiness and enabling additional value-added services.

Robust multi-source research approach combining primary stakeholder interviews, technical benchmarking, literature synthesis, and trade and policy analysis to ensure actionable insights

The research methodology underpinning this analysis combined a multi-source approach designed to provide a balanced and actionable perspective. Primary research included structured interviews with clinicians, procurement professionals, and industry executives to capture frontline usability insights and procurement priorities across hospitals, clinics, mobile testing services, physician offices, and home care programs. Secondary research involved evaluation of peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial registries to validate technological trends and clinical evidence trajectories.

Analysts synthesized qualitative inputs with technical benchmarking of assay platforms and device ergonomics, assessing how technologies such as electrochemical detection, immunoassay formats, molecular diagnostics, microfluidic implementations, and optical detection perform against real-world use cases. Trade and policy analysis examined the implications of tariff changes and procurement regulations on supply chain configurations and commercial contracts. Throughout, findings were triangulated across sources to prioritize robustness and relevance for decision-makers focused on product development, market access, and commercial operations.

Synthesis of strategic imperatives for product developers and healthcare leaders aiming to embed rapid diagnostics into care pathways and commercial ecosystems

In conclusion, point-of-care and rapid diagnostics are at a strategic inflection point where technological capability, care delivery transformation, and commercial innovation intersect to redefine where and how diagnostic decisions are made. Success in this environment will require more than strong analytical performance; it demands integrated strategies that address clinical utility, user experience, supply chain resilience, and evidence that resonates with payers and providers. Stakeholders who align product development with real-world use cases, proactively manage geopolitical and tariff-related risks, and deploy flexible distribution and commercialization models will be best positioned to capture the emerging opportunities.

Looking ahead, the emphasis will be on solutions that fit seamlessly into care pathways, provide interoperable data for clinical and population health use, and demonstrate measurable impact on outcomes and costs. For organizations willing to invest in pragmatic evidence generation, agile manufacturing partnerships, and user-centric design, the evolving landscape presents substantial opportunities to influence patient care at the point of decision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point-Of-Care Or Rapid Diagnostics Market, by Product Type

  • 8.1. Coagulation
    • 8.1.1. PT INR Meters
    • 8.1.2. Thromboelastography Devices
  • 8.2. Endocrinology
    • 8.2.1. Glucose Meters
    • 8.2.2. Insulin Pumps
  • 8.3. Hematology
    • 8.3.1. Hemoglobin Meters
    • 8.3.2. White Blood Cell Counters
  • 8.4. Immunochemistry
    • 8.4.1. Chemiluminescence Immunoassay
    • 8.4.2. Enzyme Linked Immunosorbent Assay
    • 8.4.3. Fluorescence Immunoassay
  • 8.5. Lateral Flow Immunoassays
    • 8.5.1. Antibody Tests
    • 8.5.2. Antigen Tests
    • 8.5.3. Multiplex Tests
  • 8.6. Molecular Diagnostics
    • 8.6.1. Isothermal Amplification
    • 8.6.2. Next Gen Sequencing
    • 8.6.3. PCR
  • 8.7. Urinalysis
    • 8.7.1. Analyzer Systems
    • 8.7.2. Test Strips

9. Point-Of-Care Or Rapid Diagnostics Market, by Technology

  • 9.1. Electrochemical Detection
  • 9.2. Immunoassay
    • 9.2.1. Chemiluminescence Immunoassay
    • 9.2.2. ELISA
    • 9.2.3. Fluorescence Immunoassay
    • 9.2.4. Lateral Flow Immunoassay
  • 9.3. Microfluidic Platforms
  • 9.4. Molecular Diagnostics
    • 9.4.1. Isothermal Amplification
    • 9.4.2. Next Gen Sequencing
    • 9.4.3. PCR
  • 9.5. Optical Detection

10. Point-Of-Care Or Rapid Diagnostics Market, by Sample Type

  • 10.1. Blood
  • 10.2. Breath
  • 10.3. Saliva
  • 10.4. Urine

11. Point-Of-Care Or Rapid Diagnostics Market, by Application

  • 11.1. Cardiology
  • 11.2. Diabetes Monitoring
  • 11.3. Infectious Diseases
  • 11.4. Oncology
  • 11.5. Pregnancy Testing

12. Point-Of-Care Or Rapid Diagnostics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals
  • 12.4. Mobile Testing
  • 12.5. Physician Offices

13. Point-Of-Care Or Rapid Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Point-Of-Care Or Rapid Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Point-Of-Care Or Rapid Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Point-Of-Care Or Rapid Diagnostics Market

17. China Point-Of-Care Or Rapid Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Acon Laboratories, Inc.
  • 18.7. Becton Dickinson and Company
  • 18.8. Chembio Diagnostic Systems, Inc.
  • 18.9. Danaher Corporation
  • 18.10. EKF Diagnostics Holdings plc
  • 18.11. Hologic, Inc.
  • 18.12. Jianchun Biological Technology Co., Ltd.
  • 18.13. Meridian Bioscience, Inc.
  • 18.14. Nova Biomedical Corporation
  • 18.15. OraSure Technologies, Inc.
  • 18.16. Polymer Technology Systems, Inc.
  • 18.17. QIAGEN N.V.
  • 18.18. QuidelOrtho Corporation
  • 18.19. Response Biomedical Corp.
  • 18.20. Samsung Electronics Co., Ltd.
  • 18.21. Sekisui Diagnostics, LLC
  • 18.22. Siemens Healthineers AG
  • 18.23. Sysmex Corporation
  • 18.24. Trinity Biotech plc
  • 18.25. Veredus Laboratories Pte Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PT INR METERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PT INR METERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PT INR METERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY THROMBOELASTOGRAPHY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY THROMBOELASTOGRAPHY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY THROMBOELASTOGRAPHY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMOGLOBIN METERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMOGLOBIN METERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMOGLOBIN METERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY WHITE BLOOD CELL COUNTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY WHITE BLOOD CELL COUNTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY WHITE BLOOD CELL COUNTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIGEN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANTIGEN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MULTIPLEX TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MULTIPLEX TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MULTIPLEX TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANALYZER SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANALYZER SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ANALYZER SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELECTROCHEMICAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY NEXT GEN SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY OPTICAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY OPTICAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY OPTICAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BREATH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BREATH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY BREATH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PREGNANCY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOBILE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOBILE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOBILE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY COAGULATION, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC POINT-OF-CARE OR RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS,